A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
BeOne Medicines
MSD R&D (China) Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sellas Life Sciences Group
Memorial Sloan Kettering Cancer Center
University of Zurich
Pfizer
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Peking University Third Hospital
Amgen
Regeneron Pharmaceuticals
Genmab
Autolus Limited
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Lyell Immunopharma, Inc.
AstraZeneca
Children's Hospital Medical Center, Cincinnati
Novartis
Ono Pharmaceutical Co. Ltd
SecuraBio
Dana-Farber Cancer Institute
AstraZeneca
Excyte Biopharma Ltd
Prescient Therapeutics, Ltd.
Haihe Biopharma Co., Ltd.
Amgen
Fondazione Italiana Linfomi - ETS
Australian & New Zealand Children's Haematology/Oncology Group
AbbVie
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Baylor College of Medicine
The First Affiliated Hospital of Soochow University
University of Colorado, Denver
OncoNano Medicine, Inc.
Aurigene Discovery Technologies Limited
Memorial Sloan Kettering Cancer Center
University of Utah
University of Utah
Memorial Sloan Kettering Cancer Center
University of Colorado, Denver
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Beijing InnoCare Pharma Tech Co., Ltd.
PeproMene Bio, Inc.
Fujian Medical University
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
Treeline Biosciences, Inc.
Accutar Biotechnology Inc